---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-007727"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2024-06-13T23:59:59+00:00"
generated_at: "2026-06-01T04:43:30.539381+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics expands equity pool by 400k shares; CMO shifts to part-time

## Summary
- Stockholders approved Amendment No. 1 to 2022 Stock Incentive Plan, increasing authorized shares to 400,688.
- CMO Dr. Stuart Rich will work 3 days/week from June 15, 2024; annual base salary of $333,900 prorated to 60%.
- Board elected; auditor Cherry Bekaert LLP ratified. Next advisory vote on exec compensation set for 2025 annual meeting.

## SEC filing metadata
- accession: 0001654954-24-007727
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2024-06-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495424007727/0001654954-24-007727-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495424007727/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-007727
- JSON: https://secwatch.observer/filing/0001654954-24-007727.json
- Plain text: https://secwatch.observer/filing/0001654954-24-007727.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.